June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Narrow spectrum kinase inhibitors (NSKIs) are superior to corticosteroid in both in vitro and in vivo inflammatory eye models
Author Affiliations & Notes
  • Claire Walshe
    Topivert Pharma , London, United Kingdom
  • Martyn R Foster
    Topivert Pharma , London, United Kingdom
  • Yemisi Solanke
    Topivert Pharma , London, United Kingdom
  • Sameer Sirohi
    Topivert Pharma , London, United Kingdom
  • Gayathri Devarajan
    The Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
  • John V Forrester
    The Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
  • Isabel Crane
    The Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
  • Steve Webber
    Topivert Pharma , London, United Kingdom
  • Footnotes
    Commercial Relationships   Claire Walshe, Topivert Pharma (E); Martyn Foster, Topivert Pharma (E); Yemisi Solanke, Topivert Pharma (E); Sameer Sirohi, Topivert Pharma (E); Gayathri Devarajan, Topivert Pharma (F); John Forrester, Topivert Pharma (F); Isabel Crane, Topivert Pharma (F); Steve Webber, Topivert Pharma (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3601. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Claire Walshe, Martyn R Foster, Yemisi Solanke, Sameer Sirohi, Gayathri Devarajan, John V Forrester, Isabel Crane, Steve Webber; Narrow spectrum kinase inhibitors (NSKIs) are superior to corticosteroid in both in vitro and in vivo inflammatory eye models. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3601.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Inflammatory eye diseases, such as uveitis and dry eye syndrome, can be debilitating and in severe cases lead to visual impairment. Despite recent therapeutic advances, corticosteroids (CS) followed by steroid-sparing immunosuppressants remain the mainstay treatment options. However, long term use of CS is complicated by the development of cataract and glaucoma. NSKIs are a novel class of small molecule which selectively target key kinases (p38-alpha, Src family kinases and Syk) involved in both innate and adaptive inflammatory signalling cascades. Here, we compare an NSKI to CS in in vitro and in vivo inflammatory eye models.

Methods : Efficacy and potency of the NSKI TOP1106 was compared to the CS, fluticasone propionate, using in vitro cell assays representative of innate immunity (lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMCs) and primary human macrophages), adaptive immunity (anti-CD3/anti-CD28 stimulated PBMCs) and TNFα/IL-1β stimulated primary human retinal pigment epithelial cells (RPE). In vivo, TOP1106 and dexamethasone were tested in a rat LPS-induced uveitis (EIU) model using cellular infiltrate into the aqueous humor and inflammatory cytokine levels in eye tissue as endpoints to assess efficacy.

Results : TOP1106 exhibited a broader and more potent in vitro anti-inflammatory profile compared to CS. In both innate and adaptive immune responses, TOP1106 is a potent inhibitor (IC50s < 20 nM) of inflammatory cytokine release and was superior to CS both in terms of potency and efficacy. Similarly, in stimulated RPE cells TOP1106 was markedly more potent than CS in inhibiting IL-6, IL-8 and CCL-5 release. In the EIU model, topical administration of TOP1106 (1 mg/ml) was more efficacious than CS (1 mg/ml) in reducing inflammatory cytokines MCP-1, IL-6 and IL-1β in both anterior and posterior tissues of the eye, as well as inflammatory cell infiltrate into the aqueous humor.

Conclusions : This data demonstrates the potential utility of NSKIs in the treatment of ocular inflammation. With the ability to target both innate and adaptive immunity pathways, NSKIs achieve comparable, if not superior, efficacy to CS thereby offering a potential alternative to avoid the complications of long term CS use.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×